IL-17抑制剂治疗银屑病。

Q1 Medicine

Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI:10.12788/j.sder.2018.051

So Yeon Paek, Jillian Frieder, Dario Kivelevitch, M Alan Menter

{"title":"IL-17抑制剂治疗银屑病。","authors":"So Yeon Paek, Jillian Frieder, Dario Kivelevitch, M Alan Menter","doi":"10.12788/j.sder.2018.051","DOIUrl":null,"url":null,"abstract":"The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"148-157"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"IL-17 inhibitors for psoriasis.\",\"authors\":\"So Yeon Paek, Jillian Frieder, Dario Kivelevitch, M Alan Menter\",\"doi\":\"10.12788/j.sder.2018.051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.\",\"PeriodicalId\":21714,\"journal\":{\"name\":\"Seminars in cutaneous medicine and surgery\",\"volume\":\"37 3\",\"pages\":\"148-157\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in cutaneous medicine and surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/j.sder.2018.051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2018.051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 8

摘要

Th17/白细胞介素(IL)-23通路在银屑病中的作用已被很好地阐明。IL-17家族包括6种细胞因子:IL-17A、IL-17B、IL-17C、IL-17D、IL-17E和IL-17F。两种靶向IL-17A的单克隆抗体(secukinumab, ixekizumab)和一种靶向IL-17受体的抗体(brodalumab)已被批准用于治疗中度至重度斑块性银屑病。对每种药物的临床疗效、安全性和耐受性进行了综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

IL-17 inhibitors for psoriasis.

The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in cutaneous medicine and surgery 医学-皮肤病学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.